Use of the 22C3 anti –programmed death ligand 1 antibody to determine programmed death ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients

CONCLUSIONSALS48 and BenchMark Ultra 22C3 antibody concentrate–based LDTs have been validated for PD‐L1 testing in cytology samples, and they will support reliable, high‐quality PD‐L1 testing across regions globally. Cancer Cytopathol 2018. © 2018 American Cancer Society.

Source: Cancer Cytopathology - January 1, 2018 Category: Pathology Authors: Marius Ilie, Jonathan Juco, Lingkang Huang, Veronique Hofman, Shirin Khambata ‐Ford, Paul Hofman Tags: Original Article Source Type: research